

# PROGRESS IN ENDOCRINOLOGY 1988

**Volume 2**

Proceedings of the 8th International Congress of  
Endocrinology, Kyoto, 17–23 July 1988

*Editors:*

**Hiroo Imura**

Kyoto University School of Medicine  
Kyoto, Japan

**Kazuo Shizume**

Tokyo Women's Medical College  
Tokyo, Japan

**Sho Yoshida**

Chiba University School of Medicine  
Chiba, Japan



1988

**EXCERPTA MEDICA, Amsterdam – New York – Oxford**

© 1988 Elsevier Science Publishers B.V. (Biomedical Division)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher, Elsevier Science Publishers B.V., Biomedical Division, P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.

Special regulations for readers in the USA – This publication has been registered with the Copyright Clearance Center Inc. (CCC), 27 Congress Street, Salem, MA 01970, USA. Information can be obtained from the CCC about conditions under which photocopies of parts of this publication may be made in the USA. All other copyright questions, including photocopying outside the USA, should be referred to the copyright owner, Elsevier Science Publishers B.V., unless otherwise specified.

International Congress Series No. 799  
ISBN 0 444 81041 2

*Published by:*  
Elsevier Science Publishers B.V.  
(Biomedical Division)  
P.O. Box 211  
1000 AE Amsterdam  
The Netherlands

*Sole distributors for the USA and Canada:*  
Elsevier Science Publishing Company Inc.  
52 Vanderbilt Avenue  
New York, NY 10017  
USA

*Library of Congress Cataloging in Publication Data:*

International Congress of Endocrinology (8th : 1988 :  
Kyoto, Japan)  
Progress in endocrinology 1988.

(International congress series ; no. 799)  
Includes indexes.

I. Endocrinology--Congresses. I. Imura, Hiroo.  
II. Shizume, Kazuo. III. Yoshida, Shō. IV. Title.  
V. Series. [DNLM: 1. Endocrinology--congresses.  
W3 EX89 no. 799 / WK 100 I61 1988p]  
RC648.A1I57 1988 616.4 88-31041  
ISBN 0-444-81041-2 (U.S.)



# Contents

*The contributions marked with an \* were received late and have been included at the end of this volume.*

## **Regulation of growth hormone secretion and disorders of growth**

Expression of growth hormone-releasing hormone fusion genes in transfected neuronal cells <i>K.E. Mayo and D.J. Kulik</i>	805
Central nervous system control of growth hormone secretion <i>E.E. Müller, S.G. Cella, V. de Gennaro Colonna, S. Loche, E. Ghigo, V. Locatelli, D. Cocchi, C. Pintor and F. Camanni</i>	811
Growth hormone releasing hormone therapy in growth hormone deficiency <i>W.G. Sippell and R. Hümmlink</i>	819
Growth hormone treatment of children with non-growth hormone deficient short stature <i>G. van Vliet</i>	825

## **Paracrine control of adrenocortical functions**

Actions of vasopressin on the adrenal cortex <i>A. Spät, T. Balla, P. Enyedi and A.F. Antoni</i>	831
Adrenal renin: An autocrine system modulating aldosterone production <i>P.J. Mulrow, E. Kusano, K. Baba, Y. Doi, D. Shier and R. Franco-Saenz</i>	837
Role of catecholamine- and vasoactive intestinal peptide-containing nerves in the regulation of adrenocortical functions <i>M. Holzwarth</i>	841

## **Comparative ontogeny of gonadal development**

Onset of puberty and its regulation in the bird <i>J.Y.L. Yu, C.F. Weng, S.T. Shen, L.Y. Yang and B.J. Chen</i>	849
Neuroendocrine control of female puberty in the rat <i>S.R. Ojeda, H.F. Urbanski, D. Gonzalez, L.C. Rogers and W.H. Fahrenbach</i>	855
Regulation of puberty in the lamb: Internal and external cues <i>D.L. Foster, F.J.P. Ebling, L.A. Vannerson, R.I. Wood and D.E. Fenner</i>	861
Ontogeny of the GnRH pulse generator in the rhesus monkey <i>T.M. Plant</i>	867

## **Corticotropin releasing factor/Pro-opiomelanocortin**

- Localization and distribution of glucocorticoid receptor immunoreactivity and of glucocorticoid receptor mRNA in the rat brain using immunocytochemistry and in situ hybridization  
*K. Fuxe, A. Cintra, M. Aronsson, L.F. Agnati, I. Kitayama, A.-C. Wikström, S. Okret and J.-Å. Gustafsson* 875
- Feedback regulation of ACTH secretion  
*K.J. Kovács and G.B. Makara* 885
- Regulation of corticotropin releasing factor secretion  
*P.M. Plotsky* 891
- The clinical implications of corticotropin-releasing hormone  
*P.W. Gold, M.A. Kling, H.J. Whitfield, M.A. Demitrack, G.I. Perini, K. Kalogerias, H.A. Brandt, T.D. Geraciotti and G.P. Chrousos* 897

## **Regulation of bone cell growth and function**

- Differentiation and function of osteoblasts, and bone cell derived cytokines  
*H. Fleisch, R. Felix, H. Guenther and W. Hofstetter* 915
- Paracrine regulators of bone cells  
*T.J. Martin, K.W. Ng, G. Nicholson, S. Yumita and E. Allan* 921
- TGF beta and bone remodelling  
*G.R. Mundy, L.F. Bonewald, G.D. Roodman, C. Chenu, R.O.C. Oreffo and J. Pfeilschifter* 927
- Hormonal regulation of osteoclastic bone resorption  
*T.J. Chambers* 933

## **Clinical aspects of growth hormone-insulin-like growth factor interaction**

- Growth hormone regulation of local insulin-like growth factor production  
*O.G.P. Isaksson, A. Lindahl, A. Nilsson and J. Isgaard* 941
- The different roles of IGF-I and IGF-II in growth and differentiation  
*J.J. van Wyk* 947
- Insulin-like growth factor receptors: Binding and function  
*R.G. Rosenfeld* 957
- Growth hormone binding proteins and heterogeneity of circulating growth hormone  
*G. Baumann* 965

## **Second messengers**

- Calcium signalling system  
*I. Kojima* 973
- The role of phospholipase C in signal transduction and Ca<sup>2+</sup> transport mechanisms in exocrine glands  
*I. Schulz, F. Thévenod, S. Schnefel and R. Schäfer* 977

Multiple forms of cAMP-dependent protein kinase and their role in cAMP-mediated hormone regulation and gene expression <i>S.M. Lohmann, W. Buechler, M. Meinecke and U. Walter</i>	989
Multiple small molecular weight GTP-binding proteins in bovine brain membranes <i>Y. Takai, A. Kikuchi, T. Yamashita, K. Yamamoto, M. Kawata and M. Hoshijima</i>	995
<b>Signal transduction</b>	
Primary structure and function of signal-transducing G-proteins <i>P. Gierschik, T. Bouillon, G. Hilf, R. Moghtader, D. Sidiropoulos, T. Wieland and K.H. Jakobs</i>	1003
Direct G protein gating of ionic channels <i>A. Yatani, J. Codina, R. Mattera, L. Birnbaumer and A.M. Brown</i>	1009
Role of inositol lipid metabolism in thyrotropin-releasing hormone action <i>M.C. Gershengorn</i>	1017
<b>The physiology of gonadotropin action</b>	
Mechanism of gonadotropin action – Dissociation of receptor binding and cellular activation <i>M.R. Sairam, J. Linggen, M. Dobias-Goff, J. Sairam and G.N. Bhargavi</i>	1025
Gonadotropin action on oocyte maturation <i>N. Dekel</i>	1033
Follicle stimulating hormone action on cAMP-dependent protein kinases in the ovary <i>L. Hedin</i>	1039
Interactions between the cyclic nucleotide dependent pathway and the calcium phospholipid dependent pathway in the Sertoli cell of the rat testis <i>M. Conti, L. Monaco, S.H. Hall, D.R. Joseph and F.S. French</i>	1045
<b>Regulation of thyroid growth</b>	
Thyroid growth in vivo <i>H. Studer</i>	1053
Growth factors of cultured human thyroid cells <i>T. Mori, M. Miyamoto, H. Sugawa, T. Enomoto and H. Imura</i>	1063
Iodine regulation of thyroid growth in-vitro <i>R. Gärtner, G. Bechtner, M. Rafferteder, A. Dugrillon, W. Greil and C.R. Pickardt</i>	1071
Immunoglobulins stimulating the growth of thyrocytes <i>H.A. Drexhage, M.M. Wilders, J.W. Lens and S. Boyages</i>	1077

**Endocrine aspects of hypertension**

- The renin-angiotensin system in cardiovascular tissue: From molecular biology to therapy  
*D. Ganten, S. Takahashi, R.E. Lang and T. Unger* 1089
- Role of adrenocorticotropin and corticotropin releasing factor in blood pressure control  
*B.A. Scoggins, J.P. Coghlan, A.F. Reid, C.D. Spence, J. Tresham, X. Wang and J.A. Whitworth* 1097
- Glucocorticoid and mineralocorticoid induced hypertension  
*E. Gláz, K. Rácz, R. Kiss, I. Varga, S. Orlin, L. Fütö and J. Fehér* 1103
- Atrial natriuretic factor in hypertension  
*I.G. Crozier, M.G. Nicholls, A.M. Richards, E.A. Espiner, H. Ikram and T.G. Yandle* 1111

**Opioid peptides**

- Regulation of proopiomelanocortin gene expression  
*C.-L.C. Chen* 1119
- Control of striatal enkephalin gene expression  
*J.P. Schwartz, R. Simantov, J.P. Ryan and G.R. Uhl* 1125
- Regulation of opioid receptors of the brain  
*F. Piva, D. Dondi, P. Limonta, R. Maggi and L. Martini* 1131
- Reconstitution of opioid receptors and GTP-binding proteins -signal transduction and its regulation of  $\mu$ -,  $\delta$ - and  $\kappa$ -opioid receptor systems  
*H. Ueda and M. Satoh* 1137

**Cell-cell interactions in testicular tissue**

- Peritubular myoid cell-Sertoli cell interactions  
*M.K. Skinner* 1145
- Sertoli cell-Leydig cell interactions  
*O. Avallet, M.-H. Perrard-Sapori, P. Chatelain and J.M. Saez* 1151
- Testins are Sertoli cell proteins that may be used to study cell-cell interactions within the seminiferous epithelium  
*C.Y. Chen, C.W. Bardin, C. Boitani, J. Grima and I. Morris* 1157
- Sertoli cell proteins in the human testis  
*G. Forti, G.B. Vannelli, T. Barni, C. Orlando, G.C. Balboni, R. Casano and M. Serio* 1163

**Neurohypophysial hormones**

- Vasopressin- and oxytocin-containing neurons in the CNS  
*G. Ju* 1171
- Biosynthesis of neurohypophysial hormones: The questions remaining  
*B.T. Pickering, S.D. Birkett, S.E.F. Guldenaar, J. Humphrys, H.D. Nicholson, R.T.S. Worley and W.S.B. Yeung* 1177

Vasopressin and oxytocin receptors: An overview <i>S. Jard, J. Elands, A. Schmidt and C. Barberis</i>	1183
Cerebral regulation of vasopressin secretion <i>M.J. McKinley, M. Congiu, B.J. Oldfield and G. Pennington</i>	1189
<b>Tissue renin-angiotensin systems</b>	
The renin-angiotensin systems in endocrine glands: In situ hybridization and immunocytochemistry <i>C.F. Deschepper</i>	1197
The ovarian renin-angiotensin system (OVRAS) <i>A. Lightman, A. Palumbo, P.J. Rzasa, M.D. Culler, C. Jones, V.J. Caride, A.F. Negro-Vilar, C.F. Deschepper, J.J. Ireland, A.H. Decherney and F. Naftolin</i>	1201
Testicular renin-angiotensin system <i>T. Inagami, M. Parmentier, K.N. Pandey, M. Naruse, K. Naruse and R. Pochet</i>	1207
Angiotensinogen in the brain and peripheral tissues <i>D.J. Campbell</i>	1213
<b>Gastrointestinal hormones</b>	
*New gastrointestinal hormones <i>N. Yanaihara, C. Yanaihara, T. Mochizuki, M. Hoshino, T. Zhang and K. Iguchi</i>	1545
Neuropeptides and gut hormones: Techniques for the localization of mature peptide, mRNA and specific binding sites <i>J.M. Polak and S.R. Bloom</i>	1221
VIP receptors in gut: Expression, function, structure and biosociology <i>M. Laburthe, A. Couvineau, C. Rouyer-Fessard, J. Calvo, L. Guijarro and D. Cambier</i>	1227
Bombesin-like peptide gene expression in the gastrointestinal tract <i>E.R. Spindel, I.M. Krane, M.E. Sunday, S.L. Naylor and W.W. Chin</i>	1233
<b>Endocrine aspects of osteoporosis</b>	
Estrogen and osteoporosis <i>C. Christiansen</i>	1241
Active vitamin D metabolites, calcitonin and osteoporosis <i>H. Orimo, Y. Ohuchi, T. Nakamura, A. Hattori, A.C. Souza and M. Shiraki</i>	1249
Increases in vertebral density and Ca and P retention by administration of human parathyroid hormone 1–34 plus calcitriol <i>R. Neer, D. Slovik, J. Potts Jr, M. Daly, S. Doppelt, C. Lo and D. Rosenthal</i>	1255
Fluoride treatment in osteoporosis with vertebral fractures <i>P.J. Meunier</i>	1261

## Vasoactive hormones

- Role of vasopressin in cardiovascular regulation  
*I.A. Reid* 1269
- Endogenous inhibitors of the Na<sup>+</sup> pump, hypertension, cell cytosolic Ca<sup>2+</sup> and ANP release  
*M.-A. Devynck, M.-G. Pernollet, M.J. Morris, K.-H. Le Quan Sang and P. Meyer* 1275
- Vasoactive peptides in the urogenital tract  
*B. Ottesen, C. Palle, J. Jørgensen and J. Fahrenkrug* 1283
- Neuropeptide Y and calcitonin gene related peptide  
*J.M. Allen* 1289

## Steroid binding proteins and tissue availability of hormones

- Steroid binding proteins and tissue availability of hormones  
*C. Longcope* 1297
- Molecular characteristics of plasma steroid binding proteins  
*G.L. Hammond* 1305
- Adrenocortical hormone binding proteins in different tissues  
*M.K. Agarwal* 1313
- Specific steroid binding proteins: Physiological variations and changes in diseases  
*M.G. Forest and M. Pugeat* 1319

## Advances in thyroid pathology

- Thyroid stimulators  
*S. Nagataki* 1327
- \*Autoimmune mechanisms for thyroid failure  
*A. Pinchera, G.F. Fenzi, S. Mariotti, L. Chiovato, P. Vitti, C. Marcocci, G.F. del Prete, A. Tiri, S. Romagnani and M. Ricci* 1551
- Iodine deficiency thyroid disease  
*G. Medeiros-Neto and M. Knobel* 1333
- Hyperthyroidism and periodic paralysis  
*P.P.B. Yeo, K.-O. Lee and J.S. Cheah* 1341

## Endocrine neoplasia syndromes

- Parathyroid cell mitogen in familial multiple endocrine neoplasia Type I  
*M.L. Brandi, M.B. Zimering, S.J. Marx, D. DeGrange, P. Goldsmith, K. Sakaguchi, E.A. Streeten and G.D. Aurbach* 1349
- Humoral hypercalcemia of malignancy: Identification and cloning of a PTH-like peptide  
*A.E. Broadus, M. Mangin, K. Ikeda, K.L. Insogna, E.C. Weir, W.J. Burtis and A.F. Stewart* 1357



Transforming growth factor- $\alpha$ as a possible autocrine growth factor for human adenocarcinoma of the lung <i>K. Imanishi, K. Yamaguchi, S. Honda and K. Abe</i>	1363
Somatostatin analog treatment of endocrine tumors <i>S.W.J. Lamberts and J.-C. Reubi</i>	1369

## **Prolactin**

Evolutionary origin of prolactins, growth hormones and placental lactogens <i>C.S. Nicoll and R.A. Baldocchi</i>	1379
Current concepts in the neural regulation of prolactin secretion <i>A. Negro-Vilar, C. Johnston and F.J. Lopez</i>	1385
Neuroregulation of prolactin secretion in normal human subjects <i>F.F. Casanueva, A.L. Charro, R. Valcavi, H.P. Koppeschaar and C. Dieguez</i>	1393
Interactions between prolactin and gonadotrophin secretion <i>A.S. McNeilly</i>	1399

## **MEET THE PROFESSOR**

Cushing's disease: Its diagnosis and management <i>G.M. Besser</i>	1405
Thyroid and autoimmunity <i>J. Konishi</i>	1409
Prognostic factors for recurrence and survival in breast cancer <i>W.L. McGuire</i>	1415
Gut hormones and cancers <i>Y. Miyake, K. Abe, K. Yamaguchi, N. Yanaihara and J.M. Stewart</i>	1419
Contraception <i>H.M. Zheng</i>	1423
Molecular biology: From cloning to clinic <i>J.D. Baxter</i>	1427
Non-toxic goiter <i>P.C. Scriba</i>	1433
Obesity – A disorder of intake and expenditure <i>E. Danforth Jr</i>	1437
Hyperprolactinemia <i>M.O. Thorner and M.L. Vance</i>	1441
Delayed adolescence <i>P.C. Sizonenko</i>	1445
Treatment of short stature <i>R. Rappaport</i>	1449
The thyroid and pregnancy: Developments in our understanding <i>A.M. McGregor, H.Y.M. Fung, M. Kologlu, B. Harris, C.J. Richards and R. Hall</i>	1453

Some aspects of studies of Type I diabetes in China <i>J.-L. Chen</i>	1459
The modulation of osteoclastic resorption in the therapy of bone disease <i>O.L.M. Bijvoet</i>	1463
Polycystic ovary syndrome and hirsutism <i>R.A. Lobo</i>	1467
Pituitary tumors <i>G. Faglia</i>	1473
Interrelationships of glucocorticoids and mineralocorticoids in endocrine hypertension <i>C.R.W. Edwards</i>	1477
Pathogenesis of NIDDM <i>S. Efendic</i>	1481
Hypercalcemia <i>T. Fujita</i>	1485
Male hypogonadism <i>H.W.G. Baker and A.F. Morrow</i>	1489
<b>Index of authors</b>	1557
<b>Subject index</b>	1565

## NON-TOXIC GOITER

PETER C. SCRIBA

Klinik für Innere Medizin, Medical University of Lübeck, Ratzeburger Allee 160, D 2400 Lübeck (FRG)

### ETIOLOGY

Obviously the etiology of non-toxic goiter is heterogeneous. While iodine deficiency is the predominant cause (1, 8), there are other reasons for sporadic and endemic goiter, as goitrogens from water and food supplies (2, 5), goitrogenic drugs, and in-born defects of thyroid hormone synthesis and metabolism. In addition, thyroid growth stimulating immunoglobulin may play a role, though some of the observations could have been due to contamination (4) e. g. with EGF (epidermal growth factor).

### EPIDEMIOLOGY

Non-toxic goiter remains a major health problem (1), wherever iodine deficiency prevails as an endemic problem. Recent reports show the worldwide distribution of iodine deficiency, with several hundred million people living at the risk of goiter (8). Non-toxic goiter, however, represents only the most obvious example of the whole spectrum of iodine deficiency disorders, which includes retarded growth, mental disability etc. In general it may be said, that most epidemiological data are poor and do not comply with recommendations by PAHO (14). For instance, definition by stages is not regularly applied in studies published.

A better quantization of thyroid size can be achieved by ultrasonography even in epidemiological field studies (7, 16). This procedure has an average error of 10 to 15 % and permitted to demonstrate e. g. the frequency distribution of thyroid volume in Sweden, where iodine intake suffices, as compared to the Federal Republic of Germany, where almost half of the children have enlarged thyroids (7). In addition, ultrasound patterns of the thyroid were abnormal in only 3.6 % of the Swedish adult population as compared to 16 % in Germany.

IODINE PROPHYLAXIS

The eradication of iodine deficiency carries important effects on the quality of life, the productivity and educability of those affected as summarized by the ICCIDD (8). The global prevention of this condition has been advocated by the UN and the WHO. Once installed, the maintenance of iodine prophylactic programs has to be continuously monitored.

The ETA has reported (14), that the sufficient iodine intake in Northern European countries is largely inadvertently, and for instance due to the use of iodophors as desinfectants. Only few countries like Czechoslovakia and Switzerland use adequately iodized salt. In other parts of the world, iodized oil given either intramuscularly or orally is used for prophylaxis (1, 8). We have experience with some 12 000 injections of iodized oil in Tanzania, and could not confirm the increase of thyroid antibodies as claimed by others (16).

DIAGNOSIS IN THE INDIVIDUAL : NON-TOXIC GOITER

Non-toxic goiter remains a condition, which can only be diagnosed after exclusion of other thyroid disorders. Even in countries with a well funded health system, we have to define a rational diagnostic strategy (13) in order to limit the ever increasing expenses. In Table I, the simple determination of the

TABLE I

Exclusion of	Rational procedure +)
Hypothyroidism	basal TSH (MCA)
Thyrotoxicosis	basal TSH (MCA)
Autonomy	
single nodule	Scintigraphy
multifocal/disseminated	Quantization, Suppression
Thyroiditis	
chronic	Autoantibodies
acute/subacute	ESR etc.
Nodular alterations incl.	Ultrasonography
Thyroid Malignancy	FNA - Cytology

+) NB: Sometimes more, sometimes less may be needed  
 German Society for Endocrinology - Thyroid Section (13)

basal TSH with a highly sensitive radioimmunoassay is recommended as the first and sole procedure to exclude hypothyroidism and/or thyrotoxicosis. Notably, non-toxic goiter is defined as a condition where the patient is euthyroid and free from thyroiditis or thyroid malignancy. Autonomy is excluded by scintigraphy. Sonography has become the dominating first hand procedure to diagnose thyroiditis and thyroid malignancy and is used for controlled fine needle aspiration (FNA) cytology.

#### THERAPY

As generally agreed, non-toxic goiter may be treated by surgery. There is also a place for the application of radioiodine (3) in the treatment of non-toxic goiter; certainly this kind of treatment represents a privilege of the somewhat luxurious medicine of countries with a high living standard. Patients aged 60 or older may profit most, though the reduction in thyroid size is only limited. Few if any of these patients need a thyroid hormone replacement therapy after radioiodine.

There is currently a controversy going on, whether to treat young non-toxic goiter patients with thyroxine or iodine (9). As a theoretical background, the debate continues, whether TSH is a direct growth stimulator of the thyroid. If this would be correct, TSH suppressive thyroxine doses should be the logical therapy for non-toxic goiter. Other authors consider growth factors (EGF) and the iodine content of the thyroid cell itself as important for proliferation and hyperplasia of the thyroid gland (15).

Obviously, there are non-toxic goiters with firm nodules which do not respond to medication (6). The optimal patient for medical treatment would rather be a young patient up to 25 years old with a diffuse goiter of recent onset (11). More than 80 % of these patients respond favorably to the treatment. Using sonographic volumetry as an ideal means of controlling the effect, it was shown, that size reductions by 30 - 35 % are to be expected, when thyroxine is given for a period of 3 to 6 months (12). Thereafter, no further decrease of thyroid size can be achieved.

Stopping thyroxine will lead to goiter relapse within a few weeks. Surprisingly, the relapse is slower, when iodine is applied to reduce goiter (9, 12). After successful medical therapy, one has to enter a mean of prophylaxis to prevent recurrence

of goiter by either administering half the amount of the initial thyroxine dose or by 100 to 200 µg iodine/d. What was said is true for endemic goiter in an iodine deficiency area. There are no convincing data on conservative therapy of goiters due to other causes.

As convincingly shown in children (10), treatment with iodine alone can also decrease goiter size by 30 - 40 %. The recommendation to treat adults from 25 to 40 or even 50 years of age with iodine is less clear, waiting for further studies (9). Treatment of patients with goiter by either thyroxine or iodine is not very likely to be successful after approximately 40 to 50 years of age. In patients older than this, one has to consider either surgery or radioiodine or may in other cases just observe the patient.

#### REFERENCES

1. Dunn JT et al (eds) (1986) Towards the Eradication of Endemic Goiter, Cretinism and Iodine Deficiency. PAHO Scientific Publication No 502: 1-419
2. Ermans AM et al (eds) (1980) Role of Cassava in the Etiology of Endemic Goitre and Cretinism. IDRC, Ottawa, 1-182
3. Frey KW et al (1974) Münchn med Wschr 116: 1037-1042
4. Gärtner R et al (1987) Acta Endocrinologica Suppl 281:256-259
5. Gaitan E (1986) In: Medeiros-Neto G, Gaitan E (eds) Frontiers in Thyroidology. Plenum, New York, 19-25
6. Gharib H et al (1987) N Engl J Med 317:70-75
7. Gutekunst R et al (1986) Acta Endocrinologica 112:494-501
8. Hetzel BS et al (eds) (1987) The Prevention and Control of Iodine Deficiency Disorders. Elsevier, Amsterdam, 1-354
9. Hintze G, Köbberling J (1987) Klin Wschr 65:583-589
10. Leisner B et al (1985) Acta Endocrinologica 108:44-50
11. Meng W et al (1982) Z ges inn Med 37:540-542
12. Perrild H et al (1982) Acta Endocrinologica 100:382-387
13. Scriba PC et al (1985) Int Welt 8:50-57,78-86
14. Scriba PC et al (1985) The Lancet 1:1289-1293
15. Stübner D et al (1987) Acta Endocrinologica 116:537-548
16. Wächter W et al (1987) In: Hetzel, BS et al Loc cit (8)

# INDEX OF AUTHORS

- Abe, K., 1363, 1419  
 Abendroth, D., 671  
 Acher, R., 1505  
 Adiga, P.R., 343  
 Agarwal, M.K., 1313  
 Agnati, L.F., 875  
 Albert, E.D., 165  
 Allan, E., 921  
 Allen, J.M., 1289  
 Anand-Srivastava, M.B., 185  
 Antoni, A.F., 831  
 Araki, E., 377  
 Armanini, D., 259  
 Aronsson, M., 875  
 Assan, R., 1527  
 Atger, M., 757  
 Augereau, P., 111  
 Aurbach, G.D., 1349  
 Avallet, O., 1151  
  
 Baba, K., 837  
 Bach, J.-F., 1527  
 Bailly, A., 757  
 Baker, H.W.G., 1489  
 Balboni, G.C., 1163  
 Baldocchi, R.A., 1379  
 Baldwin, B.A., 705  
 Bale, A.E., 797  
 Balla, T., 831  
 Bapat, B., 157  
 Barberis, C., 1183  
 Bardin, C.W., 1157  
 Barnard, R., 601  
 Barni, T., 1163  
 Barton, M.C., 633  
 Bassett, J.M., 125  
 Baulieu, E.-E., 413  
 Baumann, G., 965  
 Baxter, J.D., 1427  
 Bechtner, G., 1071  
 Behan, D.P., 75  
 Bergström, K., 567  
 Bergström, M., 567  
 Berkemeier, L.M., 531  
 Berry, M., 751  
 Besser, G.M., 1405  
 Bhargavi, G.N., 1025  
 Bidlingmaier, F., 165  
 Bijvoet, O.L.M., 1463  
 Birkett, S.D., 1177  
 Birnbaumer, L., 1009  
 Bloom, S.R., 1221  
 Boitani, C., 463, 1157  
 Boitard, C., 1527  
 Bonewald, L.F., 927  
 Bottazzo, G.F., 47  
 Bouillaud, F., 717  
  
 Bouillon, T., 1003  
 Boyages, S., 1077  
 Bradbury, A.F., 335  
 Branchaud, C.L., 697  
 Brandi, A.M., 553  
 Brandi, M.L., 1349  
 Brandt, H.A., 897  
 Bray, G.A., 711  
 Briozzo, P., 111  
 Broadus, A.E., 1357  
 Brown, A.M., 1009  
 Buechler, W., 989  
 Burger, H.G., 13  
 Burtis, W.J., 1357  
 Buzko, E.S., 587  
  
 Cachianes, G., 601  
 Calvo, J., 1227  
 Calza', L., 407  
 Camanni, F., 811  
 Cambier, D., 1227  
 Campbell, D.J., 1213  
 Cantin, M., 185  
 Capony, F., 111  
 Caride, V.J., 1201  
 Carino, M., 241  
 Carpene', G., 259  
 Casano, R., 1163  
 Casanueva, F.F., 1393  
 Cassard, A.-M., 717  
 Casteilla, L., 717  
 Castro, R., 685  
 Cavailles, V., 111  
 Cella, S.G., 811  
 Chambers, T.J., 933  
 Chambon, P., 751  
 Champigny, O., 717  
 Chang, T.-C., 633  
 Charlton, H.M., 525  
 Charpentier, G., 679  
 Charro, A.L., 1393  
 Chatelain, P., 1151  
 Chavez, B., 495  
 Cheah, J.S., 1341  
 Chen, B.J., 849  
 Chen, C.-L.C., 463, 1119  
 Chen, C.Y., 1157  
 Chen, E.Y., 509  
 Chen, J.-L., 1459  
 Chen, Y.I., 383  
 Chenu, C., 927  
 Chin, W.W., 525, 1233  
 Chiodini, P.G., 579  
 Chiovato, L., 1551  
 Chisari, A., 241  
 Chretien, M., 319  
 Christiansen, C., 1241

- Chrousos, G.P., 897  
 Chung, B.-C., 477  
 Cintra, A., 875  
 Claesson-Welsh, L., 503  
 Clapp, C., 559  
 Clark, A., 125  
 Clarke, I.J., 427  
 Clayton, R.N., 525  
 Clements, J.A., 469  
 Cocchi, D., 811  
 Codina, J., 1009  
 Coghlan, J.P., 1097  
 Congiu, M., 1189  
 Conti, M., 1045  
 Corbin, C.J., 483  
 Coukos, G., 407  
 Coulter, S., 35  
 Couvineau, A., 1227  
 Cox, B.S., 525  
 Cozzi, R., 579  
 Cravioto, M.C., 495  
 Crawford, C., 55  
 Crenshaw III, E.B., 725  
 Crozier, I.G., 1111  
 Culler, M.D., 1201  
 Cuthill, S., 771  
 Cutler Jr, G.B., 151
- Dallabonzana, D., 579  
 Daly, M., 1255  
 Danforth Jr, E., 1437  
 Darbre, P.D., 95  
 Dattatreya Murty, B., 195  
 De Gennaro Colonna, V., 811  
 De Kloet, E.R., 355  
 De Kretser, D.M., 13  
 Decherney, A.H., 1201  
 DeGrange, D., 1349  
 Dekel, N., 1033  
 Del Prete, G.F., 1551  
 Delgado, C., 587  
 Demitrack, M.A., 897  
 Demura, H., 401  
 Denis, M., 771  
 Derynck, R., 509  
 Deschepper, C.F., 179, 1197, 1201  
 Devynck, M.-A., 1275  
 Dieguez, C., 1393  
 Dobias-Goff, M., 1025  
 Doi, Y., 837  
 Dondi, D., 1131  
 Doppelt, S., 1255  
 Dorobek, M.D.W., 489  
 Dörr, H.G., 165  
 Dozin, B., 791  
 Drexhage, H.A., 1077  
 Drouin, J., 185  
 Dubois, C., 413  
 Dufau, M.L., 587  
 Dugrillon, A., 1071  
 Dupont, B., 55
- Ebina, Y., 377  
 Ebling, F.J.P., 861  
 Edwards, C.R.W., 1477  
 Efendic, S., 1481  
 Eisenbarth, G.S., 649  
 Elands, J., 1183  
 Emeson, R.B., 725  
 Endo, Y., 545  
 Enomoto, T., 1063  
 Enyedi, P., 831  
 Eriksson, A., 503  
 Ervin, M.G., 685  
 Espiner, E.A., 1111  
 Estivariz, F., 241  
 Euvrard, C., 413  
 Evans, W.S., 433
- Faglia, G., 1473  
 Fahrenbach, W.H., 855  
 Fahrenkrug, J., 1283  
 Fallo, F., 259  
 Fauser, B.C.J.M., 451  
 Fehér, J., 1103  
 Felix, R., 915  
 Fenner, D.E., 861  
 Fenzi, G.F., 1551  
 Ferrara, N., 559  
 Feuillan, P.P., 151  
 Feutren, G., 1527  
 Finch, C.E., 273  
 Findell, P., 559  
 Findlay, J.K., 13, 207  
 Fisher, D.A., 685  
 Fleisch, H., 915  
 Flint, A.P.F., 213  
 Forest, M.G., 1319  
 Forti, G., 1163  
 Foster, C.M., 151  
 Foster, D.L., 861  
 Franco-Saenz, R., 837  
 Frank, M., 125  
 Freiss, G., 111  
 French, F.S., 1045  
 Fricker, L.D., 329  
 Friederich, E., 325  
 Fujimoto, M., 145  
 Fujita, T., 1485  
 Fukata, J., 737  
 Funder, J.W., 247, 469  
 Fung, H.Y.M., 1453  
 Furmaniak, J., 609  
 Fütö, L., 1103  
 Fuxe, K., 875
- Ganten, D., 1089  
 Garcia, M., 111  
 Garcia, R., 185  
 Gardner, D.G., 179  
 Gärtner, R., 1071  
 Genazzani, A.R., 407  
 Genest, J., 185



- Geraciotti, T.D., 897  
 Gerdes, H.-H., 325  
 Gerendai, I., 463  
 Gershengorn, M.C., 1017  
 Gesundheit, N., 797  
 Ghigo, E., 811  
 Giardino, L., 407  
 Gierschik, P., 1003  
 Gláz, E., 1103  
 Golander, A., 395  
 Gold, P.W., 897  
 Goldsmith, P., 1349  
 Goldstein, B.J., 371  
 Gonzalez, D., 855  
 Goodyer, C.G., 697  
 Graham-Lorence, S., 483  
 Graycar, J.L., 509  
 Green, S., 751  
 Greil, W., 1071  
 Grieco, D., 791  
 Grima, J., 1157  
 Grocock, C.A., 525  
 Grossman, A., 441  
 Guenther, H., 915  
 Guijarro, L., 1227  
 Guiochon-Mantel, A., 757  
 Guise, J.W., 725  
 Guldenaar, S.E.F., 1177  
 Gustafsson, J.-Å., 771, 875  
  
 Haglund-Stengler, B., 489  
 Hai, M.T.V., 757  
 Haile-Meskel, H., 185  
 Hall, P.F., 253  
 Hall, R., 1453  
 Hall, S.H., 1045  
 Ham, J., 627  
 Hamet, P., 185  
 Hamlin, G., 601  
 Hammond, G.L., 1305  
 Hammonds, R.G., 601  
 Handelsman, D.J., 267  
 Handwerker, S., 395  
 Hanzel, W.J., 601  
 Haraguchi, K., 35  
 Harris, B., 1453  
 Hattori, A., 1249  
 Haussler, C.A., 763  
 Haussler, M.R., 763  
 Hayashizaki, H., 545  
 He, L., 469  
 Hedger, M.P., 13  
 Hedin, L., 1039  
 Heldin, C.-H., 503  
 Helqvist, S., 665  
 Henquin, J.C., 137  
 Hentz, E., 717  
 Hilf, G., 1003  
 Hinkle, P.M., 785  
 Hiraoka, Y., 545  
  
 Hofstetter, W., 915  
 Holland, F.J., 157  
 Höller, W., 165  
 Holzwarth, M., 841  
 Homo-Delarche, F., 349  
 Honda, S., 1363  
 Horiuchi, R., 779  
 Hoshijima, M., 995  
 Hoshino, M., 1545  
 Hoyt, E.C., 691  
 Hsueh, A.J.W., 451  
 Hümmelink, R., 819  
 Humphrys, J., 1177  
 Huttner, W.B., 325  
  
 Iguchi, K., 1545  
 Ikeda, K., 1357  
 Ikram, H., 1111  
 Illner, W.D., 671  
 Imanishi, K., 1363  
 Imura, H., 737, 1063  
 Inagaki, N., 81  
 Inagami, T., 1207  
 Ireland, J.J., 1201  
 Isaksson, O.G.P., 941  
 Isgaard, J., 941  
 Ishii, S., 233  
 Isogna, K.L., 1357  
 Itoh, H., 227  
 Ivell, R., 537  
 Iwashita, M., 401  
  
 Jackson, S., 241  
 Jakobs, K.H., 1003  
 Jard, S., 1183  
 Jin, J.-R., 751  
 Jingami, H., 737  
 Johnson, M.L., 433  
 Johnston, C., 1385  
 Jones, A., 525  
 Jones, C., 1201  
 Jorgensen, E.V., 395  
 Jørgensen, J., 1283  
 Joseph, D.R., 1045  
 Josso, N., 679  
 Joubert (Bression), D., 553  
 Ju, G., 1171  
 Jurutka, P.W., 763  
  
 Kahn, C.R., 371  
 Kaji, H., 785  
 Kalogeras, K., 897  
 Kangawa, K., 1495  
 Karande, A.A., 343  
 Karin, M., 639  
 Kato, K., 145, 279  
 Katzenellenbogen, B.S., 105  
 Kaufman, J.-M., 421  
 Kawata, M., 995  
 Kawauchi, H., 227

- Keinänen, K., 593  
 Kellokumpu, S., 593  
 Kikuchi, A., 995  
 King, J.A., 221  
 King, R.J.B., 95  
 Kirsch, S.E., 157  
 Kiss, R., 1103  
 Kitayama, I., 875  
 Klagsbrun, M., 517  
 Klein-Hitpass, L., 619  
 Kling, M.A., 897  
 Knobel, M., 1333  
 Knorr, D., 165  
 Kobata, A., 743  
 Kohama, S.G., 273  
 Kohn, H., 545  
 Kojima, I., 973  
 Kologlu, M., 1453  
 Komm, B.S., 763  
 Konishi, J., 1409  
 Koppeschaar, H.P., 1393  
 Kovács, K.J., 885  
 Krane, I.M., 1233  
 Krieg, M., 287  
 Kujas, M., 553  
 Kulik, D.J., 805  
 Kumar, V., 751  
 Kusano, E., 837  
 Kusuda, S., 587
- Labbe, A., 545  
 Laborie, C., 1527  
 Laburthe, M., 1227  
 Ladenheim, R., 319  
 Lamberts, S.W.J., 1369  
 Lamming, G.E., 213  
 Lancranjan, I., 579  
 Land, W., 671  
 Landgraf, R., 671  
 Landgraf-Leurs, M.M.C., 671  
 Lang, R.E., 1089  
 Långström, B., 567  
 LaPointe, M.C., 179  
 Larochele, P., 185  
 Larrea, F., 495  
 Lash, R.W., 797  
 Lazure, C., 319  
 Le Dafniet, M., 553  
 Le Quan Sang, K.-H., 1275  
 Leake, R.D., 685  
 Lechuga, M.J., 293  
 Lee, A., 509  
 Lee, K.-O., 1341  
 Lefebvre, Y., 697  
 Lens, J.W., 1077  
 Lerner, S.P., 273  
 Leung, D.W., 601  
 Lew, D., 633  
 Li, J.Y., 553  
 Lightman, A., 1201  
 Lim, A.T.W., 407
- Limonta, P., 1131  
 Lindahl, A., 941  
 Lindquist, P.B., 509  
 Linggen, J., 1025  
 Linton, E.A., 75  
 Lipes, M., 649  
 Liuzzi, A., 579  
 Lo, C., 1255  
 Lobo, R.A., 1467  
 Locatelli, V., 811  
 Loche, S., 811  
 Logeat, F., 757  
 Lohmann, S.M., 989  
 Longcope, C., 1297  
 Loosfelt, H., 757  
 Lopez, F.J., 1385  
 Lorenzo, F., 757  
 Loriaux, D.L., 151  
 Lowry, P., 75, 241  
 Lund, P.K., 691  
 Lundberg, P.O., 567  
 Lutfalla, G., 319  
 Luthman, H., 489
- Maggi, R., 1131  
 Makara, G.B., 885  
 Mandrup-Poulsen, T., 665  
 Mangin, M., 1357  
 Mantero, F., 259  
 Marcocci, C., 1551  
 Mariotti, S., 1551  
 Marrama, P., 407  
 Martin, T.J., 921  
 Martini, L., 1131  
 Marx, S.J., 1349  
 Mason, A., 531, 731  
 Mason, G.G.F., 771  
 Mathieu, M., 111  
 Mathis, J.M., 483  
 Matsubara, K., 545  
 Matsumoto, K., 99  
 Matsuo, H., 1499  
 Matsuura, M., 545  
 Mattera, R., 1009  
 Matteson, K.J., 477  
 Matthews, D.R., 125  
 Maudelonde, T., 111  
 Mayo, K.E., 805  
 Mbikay, M., 319  
 McBride, O.W., 797  
 McGregor, A.M., 1453  
 McGuire, W.L., 1415  
 McKinley, M.J., 1189  
 McLachlan, R.I., 13  
 McNeilly, A.S., 1399  
 Means, G.D., 483  
 Medeiros-Neto, G., 1333  
 Meinecke, M., 989  
 Mellon, S.H., 477  
 Mendelson, C.R., 483  
 Menezes-Ferreira, M.M., 797

- Merrill, J.C., 483  
 Metsikkö, K., 593  
 Meunier, P.J., 1261  
 Meyer, J., 763  
 Meyer, P., 1275  
 Milgrom, E., 757  
 Millar, R.P., 221  
 Miller, W.L., 477  
 Minegishi, T., 587  
 Misrahi, M., 757  
 Mitani, T., 81  
 Mitsunashi, T., 791  
 Miyai, K., 545  
 Miyake, Y., 1419  
 Miyamoto, M., 1063  
 Mochizuki, T., 1545  
 Moghtader, R., 1003  
 Mølviq, J., 665  
 Monaco, L., 1045  
 Montminy, M.R., 89  
 Morano, M.I., 241  
 Morel, Y., 477  
 Mori, T., 1063  
 Morioka, H., 791  
 Morris, I., 1157  
 Morris, M.J., 1275  
 Morris, P.L., 463  
 Morrow, A.F., 1489  
 Motta, M., 293  
 Muhr, C., 567  
 Müller, E.E., 811  
 Müller, W., 671  
 Mulrow, P.J., 837  
 Mundy, G.R., 927
- Naftolin, F., 1201  
 Nagataki, S., 1327  
 Nakagami, Y., 401  
 Nakai, Y., 737  
 Nakamura, N., 99  
 Nakamura, T., 1249  
 Nakanishi, S., 25  
 Nardulli, A.M., 105  
 Naruse, K., 1207  
 Naruse, M., 1207  
 Naylor, S.L., 1233  
 Neer, R., 1255  
 Negri-Cesi, P., 293  
 Negro-Vilar, A., 1201, 1385  
 Nemer, M., 185  
 Nerup, J., 665  
 New, M.I., 55  
 Ng, K.W., 921  
 Nicholls, M.G., 1111  
 Nicholson, G., 921  
 Nicholson, H.D., 1177  
 Nicoll, C.S., 1379  
 Niehrs, C., 325  
 Nikodem, V.M., 791  
 Nikolics, K., 531, 731  
 Nilsson, A., 941
- Nishijo, K., 545  
 Noguchi, S., 99  
 Nusser, J., 661
- O'Malley, B.W., 619  
 O'Shea, J.D., 207  
 Ohuchi, Y., 1249  
 Ojeda, S.R., 855  
 Okret, S., 875  
 Oldfield, B.J., 1189  
 Opocher, G., 259  
 Oppizzi, G., 579  
 Oreffo, R.O.C., 927  
 Orimo, H., 1249  
 Orlandi, P., 579  
 Orlando, C., 1163  
 Orlin, S., 1103  
 Ottesen, B., 1283
- Palle, C., 1283  
 Palumbo, A., 1201  
 Pandey, K.N., 1207  
 Papadopoulos, V., 253  
 Parker, M., 627  
 Parmentier, M., 1207  
 Peillon, F., 553  
 Pennington, G., 1189  
 Pepäjä, U., 593  
 Perez-Palacios, G., 495  
 Perini, G.I., 897  
 Pernollet, M.-G., 1275  
 Perrard-Sapori, M.-H., 1151  
 Perrot-Appianat, M., 757  
 Pescovitz, O.H., 151  
 Petraglia, F., 407  
 Petroncini, M., 579  
 Petty, K.J., 791  
 Pfeilschifter, J., 927  
 Philibert, D., 413  
 Picado-Leonard, J., 477  
 Pickardt, C.R., 1071  
 Pickering, B.T., 1177  
 Pinchera, A., 1551  
 Pineda, D., 587  
 Pintor, C., 811  
 Piva, F., 1131  
 Plant, T.D., 137  
 Plant, T.M., 867  
 Plotsky, P.M., 891  
 Pochet, R., 1207  
 Poellinger, L., 771  
 Polak, J.M., 1221  
 Porter Goff, A.E., 525  
 Potts Jr, J., 1255  
 Pralong, W.-F., 131  
 Pugeat, M., 1319
- Racadot, J., 553  
 Rácz, K., 1103  
 Rafferzeder, M., 1071  
 Raimbault, S., 717

- Rajaniemi, H., 593  
 Rappaport, R., 1449  
 Read, L.D., 105  
 Reaven, G.M., 383  
 Rees Smith, B., 609  
 Reichert Jr, L.E., 195  
 Reid, A.F., 1097  
 Reid, I.A., 1269  
 Reubi, J.-C., 1369  
 Ribeiro-Neto, F., 35  
 Ricci, M., 1551  
 Richards, A.M., 1111  
 Richards, C.J., 1453  
 Richards, R.G., 395  
 Richter, D., 537  
 Ricquier, D., 717  
 Risbridger, G.P., 13, 469  
 Ritzén, E.M., 489  
 Rivier, J., 407  
 Robertson, D.M., 13  
 Rocco, S., 259  
 Rochefort, H., 111  
 Rodbell, M., 35  
 Rodgers, H.F., 207  
 Rodgers, R.J., 207  
 Rogelj, S., 517  
 Rogers, L.C., 855  
 Rogol, A.D., 433  
 Romagnani, S., 1551  
 Roodman, G.D., 927  
 Rosa, P., 325  
 Rosenfeld, M.G., 725  
 Rosenfeld, R.G., 957  
 Rosenthal, D., 1255  
 Ross, M.G., 685  
 Rossier, B.C., 361  
 Rougeon, R., 319  
 Rouyer-Fessard, C., 1227  
 Russo, A.F., 725  
 Ryan, J.P., 1125  
 Rzasas, P.J., 1201  
  
 Saez, J.M., 1151  
 Sairam, J., 1025  
 Sairam, M.R., 1025  
 Sakaguchi, K., 1349  
 Sakiz, E., 413  
 Saper, C.B., 173  
 Sato, B., 99  
 Satoh, M., 1137  
 Savouret, J.-F., 757  
 Sawchenko, P., 407  
 Schäfer, R., 977  
 Schechter, J., 559  
 Schmale, H., 537  
 Schmidt, A., 1183  
 Schneffel, S., 977  
 Scholz, S., 165  
 Schulman, B.A., 763  
 Schulz, I., 977  
 Schwartz, J.P., 1125  
  
 Scoggins, B.A., 1097  
 Scott, I., 525  
 Scriba, P.C., 1433  
 Seeburg, P., 531, 731  
 Seidah, N.G., 319  
 Seino, Y., 81  
 Sellen, J.-M., 697  
 Serio, M., 1163  
 Seshagiri, P.B., 343  
 Severinsson, L., 503  
 Shaha, C., 457  
 Shapiro, D.J., 633  
 She, S.T., 849  
 Sherman, D.J., 685  
 Sheth, A.R., 301  
 Sheth, N.A., 301  
 Shier, D., 837  
 Shimada, F., 377  
 Shiraki, M., 1249  
 Shizume, K., 3, 401  
 Shoelson, S.E., 371  
 Sidiropoulos, D., 1003  
 Simantov, R., 1125  
 Simpson, E.R., 207, 483  
 Sippell, W.G., 819  
 Sirmai, J., 1527  
 Sizonenko, P.C., 1445  
 Skinner, M.K., 1145  
 Slovik, D., 1255  
 Smith, A.I., 247, 469  
 Smyth, D.G., 335  
 Snider, C.E., 105  
 Solish, S.B., 477  
 Sollenberger, M.J., 433  
 Song, M.-K., 791  
 Souza, A.C., 1249  
 Spät, A., 831  
 Speiser, P.W., 55  
 Spence, C.D., 1097  
 Spencer, S.A., 601  
 Spindel, E.R., 1233  
 Spinedi, E., 241  
 Stewart, A.F., 1357  
 Stewart, H.J., 213  
 Stewart, J.M., 1419  
 Stewart, T.A., 531  
 Streeten, E.A., 1349  
 Stuchbery, S.J., 207  
 Studer, H., 1053  
 Suda, T., 401  
 Sugawa, H., 1063  
 Sumitomo, T., 401  
 Sunday, M.E., 1233  
 Sutton, S., 407  
 Suzuki, K., 227  
 Swanson, P., 227  
  
 Takahashi, H., 81, 737  
 Takahashi, S., 1089  
 Takai, Y., 995  
 Takeda, J., 81

- Tamm, J., 509  
 Tanaka, K., 81  
 Teni, T.R., 301  
 Terpening, C.M., 763  
 Thévenod, F., 977  
 Thibault, G., 185  
 Thiele, E.A., 329  
 Thomson, A., 627  
 Thorner, M.O., 1441  
 Thureau, S., 671  
 Tiri, A., 1551  
 Tomori, N., 401  
 Tozawa, F., 401  
 Tresham, J., 1097  
 Trimble, E.R., 119  
 Tsai, M.-J., 619  
 Tsai, S.Y., 619  
 Tsukada, T., 737  
 Tunn, S., 287
- Uchida, N., 99  
 Udrisar, D., 35  
 Ueda, H., 1137  
 Uhl, G.R., 1125  
 Ulloa-Aguirre, A., 495  
 Ulmann, A., 413  
 Unger, T., 1089  
 Urban, R.J., 433  
 Urbanski, H.F., 855  
 Usala, S.J., 797  
 Ushiyama, T., 401  
 Usui, T., 737
- Valcavi, R., 1393  
 Vale, W., 407  
 Van Vliet, G., 825  
 Van Wyk, J.J., 947  
 Vance, M.L., 1441  
 Vannelli, G.B., 1163  
 Vannerson, L.A., 861  
 Varga, I., 1103  
 Veldhuis, J.D., 433  
 Vigier, B., 679  
 Vignon, F., 111  
 Visweswariah, S.S., 343  
 Vitti, P., 1551  
 Volpe, A., 407  
 Voutilainen, R., 477
- Wallace, C.A., 247  
 Walter, U., 989  
 Wang, X., 1097  
 Waterman, M.R., 207  
 Waters, M.J., 601
- Waxman, J., 307  
 Webster, N., 751  
 Weick, R., 157  
 Weilgosz, G., 157  
 Weinberger, C., 797  
 Weiner, R., 559  
 Weintraub, B.D., 797  
 Weir, E.C., 1357  
 Wen, D., 509  
 Weng, C.F., 849  
 Westermarck, B., 503  
 White, L.B.S., 247  
 White, P.C., 55  
 Whitfield, G.K., 763  
 Whitfield, H.J., 897  
 Whitworth, J.A., 1097  
 Wieland, T., 1003  
 Wikström, A.-C., 875  
 Wilders, M.M., 1077  
 Wilhelmsson, A., 771  
 Wilson, K., 649  
 Wogensen, L.D., 665  
 Wollheim, C.B., 131  
 Wondisford, F.E., 797  
 Wood, R.I., 861  
 Wood, W.I., 601  
 Woodcock, E.A., 247  
 Worley, R.T.S., 1177  
 Wu, J., 179  
 Wu, Y.Q., 395
- Yamaguchi, K., 1363, 1419  
 Yamamoto, K., 995  
 Yamashita, T., 995  
 Yanagibashi, K., 253  
 Yanaihara, C., 1545  
 Yanaihara, N., 1419  
 Yandle, T.G., 1111  
 Yang, L.Y., 849  
 Yaniahara, N., 1545  
 Yano, H., 81  
 Yatani, A., 1009  
 Yeo, P.P.B., 1341  
 Yeung, W.S.B., 1177  
 Yu, J.Y.L., 849  
 Yumita, S., 921
- Zaccardo, A.M., 407  
 Zeleznik, A.J., 201  
 Zhang, T., 1545  
 Zheng, H.M., 1423  
 Zimering, M.B., 1349  
 Zoppi, S., 293



# SUBJECT INDEX

*Prepared by E.A. van der Veen, M.D., Amsterdam, The Netherlands*

- acetylcholine
  - GH secretion, 815
- acromegaly
  - GRH, GH secretion, 9
  - medical treatment, 580
  - somatostatin, 581
  - somatostatin analog, 1369
  - somatostatin, treatment, 10
- ACTH
  - adrenal cell form, 253
  - aldosterone synthesis, 249
  - angiotensin II, 249
  - blood pressure control, 1097
  - CRF, cortisol, test, 3
  - guinea pig, 247
  - phosphatidylinositol, 249
  - placenta, 408
  - pregnancy, 401
- ACTH secretion
  - hypoglycemia, 5
  - regulation, 885
  - vasopressin, 5
- activin
  - FSH secretion, 13
  - ovary, 453
- adrenal adenoma
  - hypertension, 1105
- adrenal androgen
  - aging, 279
- adrenal cell
  - ACTH, cell form, 253
  - cholesterol transport, 256
  - cytoskeleton, 255
- adrenal cortex
  - autonomic nervous system, 841
  - vasopressin, 831
  - VIP, 841
- adrenal gland
  - aging, 279
  - pro-opiomelanocortin, growth, 241
  - renin, 837
  - vitamin E, 279
- adrenal insufficiency
  - vasopressin, 1273
- adrenal steroids
  - food intake, 714
- adrenergic system
  - LHRH secretion, 436
- adrenodoxin
  - cholesterol side chain cleavage, 477
- aging
  - adrenal androgen, 279
  - adrenal gland, 279
  - estrogen, 273
  - estrous cycle, 273
  - GH secretion, 812
  - hypothalamo-pituitary-gonadal axis, 267
  - neuroendocrine function, 273
  - semen analysis, 268
  - testis size, 269
  - testosterone blood level, 271
- aldosterone
  - sodium transport, 362
- aldosterone production
  - renin, 837
  - vasopressin, 831
- aldosterone synthesis
  - ACTH, 249
  - angiotensin II, 249
- amidating enzyme
  - peptide hormone, 335
- amiloride
  - sodium transport, 364
- androgen
  - LHRH secretion, 434
- androgen binding protein
  - Sertoli cell, 1166
- androgen metabolism
  - LHRH analogue, 293
- androgen receptor
  - mammary carcinoma, 95, 99
- androgen receptor defect
  - hypogonadism, 1489
- androgen response element
  - 627
- ANF
  - fetus, 685
  - hypertension, 1111
- angiogenesis
  - ovary-renin-angiotensin system, 1205
- angiotensin
  - central nervous system, 1091
  - Leydig cell, 1209
- angiotensin II
  - ACTH, 249
  - aldosterone synthesis, 249
- angiotensinogen
  - central nervous system, 1213

- glycosylation, 1213
- tissue distribution, 1216
- anorexia nervosa
  - CRF, 6
- ANP
  - cardiomyopathy, hamster, 188
  - digitalis-like substance, 1275
  - gene expression, 179
  - histochemistry, heart, 186
  - hypertension, 189
  - immunohistochemistry, 174
  - pathophysiology, 185
  - precursor, 1496
  - vassopressin, 175
- anti-Müllerian hormone
  - aromatase, 681
  - fetal ovary, 679
- antiestrogen
  - MCF-7 breast cancer cells, 106
- antiluteolysin
  - 213
- antiprogesterone
  - 413
  - contraception, 416
  - progesterone receptor, 414
- arginine vasopressin
  - see vasopressin
- aromatase
  - anti-Müllerian hormone, 681
  - gene regulation 483
  - prostate, 294
- aromatase inhibitor
  - 4-OH-androstenedione, 295
- arteriogenesis
  - prolactinoma, 559
- atrial natriuretic peptide
  - see ANP
- autoimmunity
  - beta cell destruction, 649
  - thyroid stimulator, 1327
- autonomic nervous system
  - adrenal cortex, 841
- basic fibroblast growth factor
  - MEN I, 1354
- beta cell
  - autoimmune destruction, 649
- beta cell destruction
  - interleukin I, 666
  - tumor necrosis factor, 666
- bisphosphonate
  - bone resorption 1463
  - hypercalcemia, 1465
  - osteoporosis, 1465
  - Paget's disease, 1464
- blood pressure
  - ACTH, 1097
  - CRF, 1097
- bombesin
  - food intake, 706
- bombesin-like peptide
  - gastrointestinal tract, 1233
  - gene expression, 1233
- bone density
  - calcitriol, 1255
  - parathyroid hormone, 1255
- bone resorption
  - bisphosphonate, 1463
  - transforming growth factor beta, 927
- brain natriuretic peptide
  - 173
  - identification, 1499
  - structure, 1497
- Battleboro rat
  - vasopressin deficiency, 537
  - vasopressin precursor, 1177
- breast cancer
  - prognosis, 1415
  - steroid receptor, 1415
- bromocriptine
  - amino acid metabolism, 572
  - PET-scan, 568
  - prolactin synthesis, 563
- brown adipose tissue
  - human histology, 721
  - uncoupling protein, 717
- busurelin
  - precocious puberty, 145
- calcitonin
  - osteoclast, 934
  - osteoporosis, 1249
- calcitonin gene
  - 725
- calcitonin gene related peptide
  - neuropeptide Y, 1289
- calcitriol
  - bone density, 1255
- calcium
  - insulin release, 131
  - calcium signalling system
  - IGF II, 973
- calcium transport mechanism
  - phospholipase C, 977
- cAMP
  - gene expression, 89
- cAMP-dependent protein kinase
  - 989
- cancer
  - gut hormone, 1419
- carbachol
  - insulin secretion, 131
- carboxypeptidase E
  - 329
- carcinogenesis
  - see oncogenesis
- carcinoid
  - somatostatin analog, 1371
- cardiac output



- vasopressin, 1270
- cardiomyopathy
  - ANP, hamster, 188
- castration
  - LHRH secretion, 428
- catecholamine
  - GH secretion, 813
- cathepsin
  - estrogen, 111
  - mammary carcinoma, 111
- central nervous system
  - angiotensinogen, 1213
  - corticosteroid receptor, 355
  - glucocorticoid receptor, rat, 875
  - stress, 355
- cerebrospinal fluid
  - CRF-level, 5
- cholecystokinin
  - food intake, 705
- cholesterol
  - adrenal cell, transport, 256
- cholesterol desmolase deficiency
  - 60
- cholesterol side chain cleavage
  - adrenodoxin, 477
- chromogranin
  - 326
  - neuroendocrine system, 1221
- colony stimulating factor
  - bone cell, 918
- congenital adrenal hyperplasia
  - epidemiology, 61
  - inheritance, 500
  - review, 55
  - treatment, 165
- congenital hypothyroidism
  - TSH deficiency, 545
- contraception
  - antiprogestosterone, 416
- contraception programmes
  - China, 1423
- corpus luteum
  - inhibin, 210
  - interferon, 213
  - structure, function, 207
- corticosteroid
  - CRF secretion, 893
- corticosteroid binding protein
  - structure, 1305
- corticosteroid receptor
  - central nervous system, 355
- corticotrophin releasing hormone
  - see CRF
- cortisol
  - CRF, ACTH, test, 3
- CRF
  - ACTH, cortisol, test, 3
  - anorexia nervosa, 6
  - binding protein, 75, 403
  - blood pressure control, 1097
  - corticospinal fluid, 5
  - food intake, 706
  - pituitary adrenal axis, 899
  - placenta, 403
  - pregnancy, 401
  - psychiatric disorder, 901
  - review, 897
  - stress response, 904
- CRF secretion
  - corticosteroid, 893
  - regulation, 891
- CRF test
  - 900
  - Cushing's disease, 4, 906
  - depression, 906
- Cushing's disease
  - CRF-test, 4, 906
  - medical treatment, 582
  - review, 1405
- cyclosporine
  - type I diabetes mellitus, 1527
- cyproterone acetate
  - prostate cancer, 308
- cytochrome P450 enzyme
  - steroidogenesis, 477
- cytokine
  - osteoblast, 915
  - thyroid cell, 1329
- cytoplasmic islet cell antibody
  - 651
- cytoskeletal
  - 35
  - adrenal cell, 255
- deglycosylation
  - glucoprotein hormone, 1025
- delayed puberty
  - hypergonadotropic hypogonadism, 1445, 1446
  - review, 1448
- depression
  - CRF-test, 906
- diabetes mellitus
  - beta cell destruction, 649
  - pathogenesis, review, 665
  - restriction fragment length polymorphism, 1460
- diabetes mellitus I
  - China, 1459
  - cyclosporine, 1527
- digitalis-like substance
  - ANP, 1275
  - essential hypertension, 1277
- dioxin receptor,
  - 771
- DNA binding protein
  - gene expression, 639
- dopamine
  - LHRH secretion, 437
- dopamine receptor

- PET-scan, 568
- elcatonin
  - osteoporosis, 1253
- endemic goiter
  - malnutrition, 1336
  - superoxide dismutase, 1338
- endocrine hypertension
  - steroid excess syndrome, 1477
- endocrine pancreas tumor
  - somatostatin, 1371
- endogenous opiate
  - LHRH secretion, 433
- enkephalin
  - central nervous system, 1125
  - convertase, 329
  - gene expression, 1125
- epidermal growth factor
  - gonads, 452
- erection
  - VIP, 1286
- essential hypertension
  - digitalis-like substance, 1277
- estradiol clearance rate
  - free hormone level, 1299
- estrogen
  - aging, 273
  - cathepsin, 111
  - LHRH secretion, 435
  - neuroendocrine function, 273
  - opioid receptor, 1132
  - osteoporosis, 1241
  - prolactinoma, 559
  - prostate, 289
  - retinol binding protein, 635
  - riboflavin carrier protein, 343
  - vitellogenin gene transcription, 633
- estrogen receptor
  - 621
  - activation domain, 751
  - hormone responsive element, 751
  - mammary carcinoma, 105
- estrogen response element
  - 621, 627
- estrous cycle
  - aging, 273
  - LHRH secretion, 428
  - opioid receptor, 1131
- exercise
  - LHRH secretion, 441
  - steroid binding protein, 1323
- fertility control
  - antiprogestosterone, 413
- fibroblast growth factor
  - gonads, 454
  - oncogenesis, 517
  - signal peptide, 517
- fluoride
  - osteoporosis, 1242, 1261
- flutamide
  - LHRH secretion, 435
  - prostate cancer, 308
- follicle fluid
  - angiotensin, 1201
  - renin, 1201
  - steroidogenic enzyme, 208
- follistatin
  - FSH-secretion, 13
- food intake
  - adrenal steroids, 714
  - bombesin, 706
  - cholecystokinin, 705
  - CRF, 706
  - glucagon, 707
  - insulin, 707
  - neuropeptide, 705
  - neurotensin, 706
  - neurotransmitter, 713
  - opioid peptides, 708
  - regulation, review, 711
- free fatty acid metabolism
  - NIDDM, 389
- FSH
  - LHRH secretion, 430
  - ovary follicle growth, 202
  - protein kinase, 1039
  - pulsatile administration, 201
  - receptor binding, 196
  - sugar chain structure, 747
- FSH receptor
  - antibodies, 199
  - solubilization, 195
- FSH-secretion
  - activin, 13
  - follistatin, 14
- galanin
  - gastrointestinal hormone, 1545
  - insulin secretion, 1546
- gastrin-releasing peptide
  - analogue, 1420
  - small cell lung carcinoma, 1363
  - structure, 1234
- gastrin-releasing peptide receptor
  - blocking peptide, 1420
- gene expression
  - neuroendocrine system, 725
  - POMC, pituitary, 737
  - regulation, cAMP, 89
- GH
  - somatostatin, 811
- GH binding protein
  - 602, 965
- GH deficiency
  - GRF therapy, 819
  - GRH treatment, 8
  - treatment, 1449
- GH gene

- expression, 640
- GH secretion
  - acetylcholine, 815
  - acromegaly, GRH, 9
  - aging, 812
  - catecholamine, 813
  - GRF, 811
  - pirenzepine, 815
  - regulation, 811
- GH treatment
  - pulsatile administration, 942
  - short stature, 825
  - Turner syndrome, 826
- GH-cell
  - T3, 785
- GHRH
  - see also GRF
  - prolactin secretion, 1395
- GIP precursor
  - 81
- glucagon
  - food intake, 707
- glucagon-like peptide I
  - insulin secretion, 1548
- glucocorticoid
  - circulating cells, 350
  - gamma-interferon, 352
  - immune response, 349
  - interleukin, 351
  - lymphokine, 352
  - thymic hormone, 352
- glucocorticoid receptor
  - 771
  - central nervous system, rat, 875
  - hormone responsive element, 751
  - mammary carcinoma, 96
- glucose intolerance
  - insulin resistance, 383
- glycoprotein
  - sugar chain structure, 743
- glycoprotein hormone
  - deglycosylation, 1025
- GNRH
  - see also LHRH
  - evolution, 221
- goitre
  - thyroid growth, 1053
  - thyroid growth stimulating
- gonadotroph
  - immunochemistry, 230
- gonadotropin
  - amino acid composition, vertebrate, 235
  - fish, 227
  - mechanism of action, 1025
  - oocyte maturation, 1033
- gonadotropin deficiency
  - hypogonadism, 1491
- gonadotropin receptor
  - evolution, 233
- Graves' disease
  - TSH-binding inhibitor, 1409
  - TSH-receptor antibody, 1410
- GRF
  - fetal pituitary, 697
  - gene, promoter activity, 805
  - GH secretion, 811
- GRF therapy
  - GH deficiency, 819
  - GH deficiency, treatment, 8
  - GH secretion, 6
- growth
  - insulin-like growth factor, 947
- growth factor
  - bone formation, 923
  - gonad, 451
  - gut hormone, 1419
  - mammary carcinoma, 99
  - osteoblast, 915
  - Sertoli cell, 1154
- growth hormone
  - evolutionary origin, 1379
  - heterogeneity, 965
  - insulin-like growth factor, 941
- growth hormone receptor
  - 601
- growth hormone releasing factor
  - see GRF
- growth hormone releasing hormone
  - see GRH
- growth hormone secretion
  - GRH, 6
- GTP-binding protein
  - 35
  - forms, 995
  - ionic channel regulation, 1009
  - opioid receptor, 1137
  - structure, function, 1003
- gut hormone
  - cancer, 1419
  - growth factor, 1419
- hCG
  - sugar chain structure, 743
- hCG receptor
  - gonad, 587
- helodermin
  - insulin secretion, 1549
- high density lipoprotein
  - placental lactogen secretion, 395
- hirsutism
  - polycystic ovary syndrome, 1467
- HLA antigen
  - type IDDM, China, 1459
- hormone responsive element
  - estrogen receptor, 751
  - glucocorticoid receptor, 751
- 4-hydroxy-androstenedione
  - aromatase inhibitor, 295
- 6 beta-hydroxycortisol

- hypertension, 1478
- 21-hydroxylase
  - cytochrome P450 enzyme, 479
- 21-hydroxylase deficiency
  - 55
  - restriction length polymorphism, 489
- 17-alpha hydroxylase
  - cytochrome P450 enzyme, 478
- 17 alpha-hydroxylase deficiency
  - 60
- 11 beta-hydroxylase deficiency
  - 59
- 3-beta-hydroxysteroid dehydrogenase
  - deficiency, 59, 495
- hyperaldosteronism
  - hypertension, review, 259
- hypercalcemia
  - bisphosphonate, 1465
  - cancer, 1357
  - PTH-like peptide, 1357
  - review, 1486
- hypergonadotropic hypogonadism
  - delayed puberty, 1445, 1446
- hyperparathyroidism
  - growth factor, 1351
- hyperprolactinemia
  - dopaminergic drugs, 1444
  - review, 1441
- hypertension
  - adrenal adenoma, 1105
  - ANF, 1111
  - ANP, 189
  - corticosteroid induced form, 1103
  - hyperaldosteronism, review, 259
- hypothyroidism
  - periodic paralysis, 1341
  - T-cell subset, 1328
- hypoglycemia
  - ACTH secretion, 5
- hypogonadism
  - androgen receptor defect, 1489
  - mouse model, 525, 531
  - seminiferous tubule failure, 1489
- hypothalamus-pituitary-gonadal axis
  - aging, 267
  - puberty, duck, 849
  - puberty, rat, 855
- hypothalamus-pituitary-adrenal axis
  - 885
- hypothyroidism
  - autoimmunity, 1551
  - TSH-gene, 545
  - TSH-receptor antibody, 1411
- IGF-receptor
  - structure, function, 957
- immune response
  - glucocorticoid, 349
- in situ hybridization
  - renin-angiotensin system, 1197
- inhibin
  - corpus luteum, 210
  - growth factor, 453
  - immunocytochemistry, 461
  - infertility, 1491
  - isolation, 13
  - placenta, 409
  - prostate, 301
  - review, 13
- inositol lipid metabolism
  - TRH, 1017
- inositol phosphate production
  - 979
- insulin
  - food intake, 707
- insulin autoantibody,
  - 650
- insulin-like growth factor II
  - adrenal cell, 481
- insulin receptor
  - 377
  - activation, synthesis, 371
- insulin receptor gene
  - 373, 378
- insulin release
  - calcium, 131
- insulin resistance
  - glucose intolerance, 383
  - non-insulin-dependent diabetes, 383
- insulin secretion
  - carbachol, 131
  - electrophysiology, 137
  - first phase, 653
  - galanin, 1546
  - glucagon-like peptide, 1548
  - helodermin, 1549
  - neural control, 119
  - pulsatility, 125
  - somatostatin, 128
  - VIP, 120
- insulin-like growth factor
  - fetus, 691
  - growth hormone, 941
  - growth, differentiation, 947
  - nutrition, 949
  - ovary, 452
  - Sertoli cell, 1164
  - testis, 452
- insulin-like growth factor II
  - calcium signalling system, 973
- interferon
  - corpus luteum, 213
  - pregnancy, 213
  - thyroid T-cell, 1554
- interferon-(g)
  - antigen expression, 1328
- gamma-interferon
  - glucocorticoid, 352
- interleukin

- glucocorticoid, 351
- interleukin I
  - beta cell destruction, 666
- iodine
  - thyroid growth, 1071
- iodine deficiency
  - superoxide dismutase, 1333
  - thyroglobulin, 1333
- islet cell transplantation
  - China, 1461
- kallikrein
  - cDNA structure, rat, 319
- lactogen receptor
  - gonad, 591
- Leydig cell
  - angiotensin, 1209
  - renin, 1208
  - Sertoli cell interaction, 1151
  - vasopressin, 1180
- LH
  - mechanism of action, 1034
  - pulsatile administration, 201
  - sugar chain structure, 746
- LH pulsatility
  - oligospermia, 1492
- LH pulse frequency
  - 864
  - photoperiod, 864
- LH receptor
  - gonad, 587
  - structure, 593
- LH secretion
  - puberty, sheep, 861
- LHRH
  - gene analysis, 531
  - placenta, 408
  - prolactin secretion, 1395
  - pulse generator, 421
- LHRH agonist
  - busurelin, 145
- LHRH analogue
  - androgen metabolism, prostate, 293
- LHRH deficiency
  - mouse, 525
  - mutant gene, 531
  - pituitary gonadal axis, 526
  - sexual differentiation, 525
- LHRH gene
  - mouse mutant, 531
- LHRH neuron
  - N-methyl-D-aspartate, 869
  - neuronal growth factor, 858
- LHRH precursor
  - structure, 731
- LHRH pulse generator
  - ontogeny, monkey, 867
- LHRH secretion
  - castration, 428
  - electrophysiology, 421
  - endogenous opiate, 433
  - estrous cycle, 428
  - exercise, 441
  - feedback system, 427
  - flutamide, 435
  - FSH, 430
  - puberty, 856
  - pulse generator, 433
- lung carcinoma
  - gastrin-releasing peptide, 1363
  - growth factors, 1363
- luteal cell
  - origin, 207
  - steroidogenic enzyme, 208
- luteolysin
  - 213
- 17,20 lyase deficiency
  - 60
- lymphokine
  - glucocorticoid, 352
- malic enzyme gene
  - structure, 794
- malic enzyme mRNA
  - T3, 791
- malnutrition
  - endemic goiter, 1336
  - steroid binding protein, 1323
- mammary carcinoma
  - androgen receptor, 99
  - cathepsin, 111
  - estrogen receptor, 105
  - growth factors, 99
  - progesterone receptor, 105
  - tumour growth factor, 97
- mammary tumour
  - steroid responsiveness, 95
- McCune-Albright syndrome
  - precocious puberty, 151
- mineralocorticoid
  - amphibian model, 361
- molecular biology
  - review, 1427
- motilin precursor
  - 81
- multiple endocrine neoplasia I
  - parathyroid cell mitogen, 1349
- N-methyl-D-aspartate
  - LHRH neuron, 869
- natriuretic peptide
  - brain and heart, 1499
- neuroendocrine system
  - gene expression, 725
- neurohypophysial hormone
  - evolution, 1507
- neuromedin B
  - ranatensin analogue, 1233
- neuromedin K

- 25
- neuronal growth factor
  - LHRH neuron, 858
- neuropathy
  - pancreas transplantation, 673
- neuropeptide
  - autoradiography, 1223
  - binding site, 1223
  - food intake, 705
  - localization technique, 1221
- neuropeptide precursor
  - 25
- neuropeptide receptor
  - 25
- neuropeptide Y
  - calcitonin gene related peptide, 1289
  - urogenital tract, 1283
- neurophysin
  - evolution, 1514
  - review, 1505
- neurotensin
  - food intake, 706
- neurotransmitter
  - CRF secretion, 892
  - food intake, 713
- non-insulin dependent diabetes mellitus
  - pathogenesis, 1481
  - insulin resistance, 383
- non-toxic goiter
  - review, 1433
- norepinephrine
  - uncoupling protein, 719
- nutrition
  - insulin-like growth factor, 949
- obesity
  - energy expenditure, 1437
  - uncoupling protein, 719
- 18-OH-cortisol
  - hypertension, 1477
- oligospermia
  - LH pulsatility, 1492
- oncogenesis
  - fibroblast growth factor, 517
- oocyte
  - LH action, 1033
- opiate antagonist
  - testis, 466
- opioid peptides
  - food intake, 708
- opioid receptor
  - central nervous system, 1125
  - estrous cycle, 1131
  - GTP-binding protein, 1137
- osmoreceptor
  - vasopressin secretion, 1189
- osteoblast
  - cytokine, 915
  - growth factor, 915
  - regulation, 933
  - transforming growth factor beta, 928
- osteoclast
  - activation, 921
  - calcitonin, 934
- osteoclast activating factor
  - 918
- osteoporosis
  - bisphosphonate, 1465
  - calcitonin, 1249
  - elcatonin, 1253
  - estrogen, 1241
  - fluoride, 1242, 1261
  - histomorphometry, 1262
  - vitamin D metabolite, 1249
  - vitamin D3, 1242
- ovary
  - activin, 453
  - epidermal growth factor, 452
  - FSH action, 1039
  - renin-angiotensin system, 1201
- ovary follicle
  - growth, FSH, 202
- ovulation
  - ovary-renin-angiotensin system, 1204
- oxytocin
  - central nervous system, 1171
  - gonad, 469
  - prolactin secretion, 1386
- oxytocin receptor
  - review, 1183
- Paget's disease
  - bisphosphonate, 1464
- pancreas transplantation
  - neuropathy, 673
  - retinopathy, 674
  - type I diabetes, 671
- pancreastatin
  - 325
- parathyroid cell mitogen
  - MEN I, 1349
- parathyroid hormone
  - bone density, 1255
- periodic paralysis
  - hyperthyroidism, 1341
- peritubular myoid cell
  - cell-cell-interaction, 1145
- pertussis toxin
  - 39
- phosphatidylinositol
  - ACTH, 249
- phospholipase C
  - calcium transport, 977
- photoperiod
  - LH pulse frequency, 864
- phyllolitorin
  - bombesin-like peptide, 1233

- pirenzepine
  - GH secretion, 816
- pituitary adenoma
  - medical treatment, review, 579
  - pathology, review, 553
- pituitary adrenal axis
  - CRF, 899
  - guinea pig, 247
- pituitary cell culture
  - T3, 785
- pituitary gland
  - fetal, GRF, 697
  - fetal, somatostatin, 697
- pituitary gonadal axis
  - LHRH deficiency, 526
- pituitary tumor
  - review, 1473
- placenta
  - ACTH, 408
  - CRF, 403, 407
  - inhibin, 409
  - LHRH, 408
- placental lactogen
  - evolutionary origin, 1379
  - high density lipoprotein, 395
  - releasing factor, 398
  - secretion, 395
- plasminogen activator
  - bone, 923
- platelet derived growth factor
  - bone formation, 916
  - receptor structure, 503
- polycystic ovary syndrome
  - hirsutism, 1467
- POMC
  - gene expression, 737
- POMC-derived peptide
  - gonad, 463, 471
  - testis, 457
- positron emission tomography
  - dopamine receptor, 568
  - pituitary adenoma, 567
- precocious puberty
  - busurelin, 145
  - familial form, 157
  - McCune-Albright syndrome, 151
  - testolactone, 155
- pregnancy
  - ACTH, 401
  - CRF, 401
  - interferon, 213
  - thyroid function, 1453
- pro-hormone
  - kallikrein, 319
  - proteinase, 319
- pro-opiomelanocortin receptor
  - adrenal gland, growth, 241
- progesterone
  - opioid receptor, 1132
- progesterone antagonist
  - fertility control, 413
- progesterone receptor
  - 620
  - antiprogesterone, 414
  - gene interaction, 760
  - human cancer cell, 759
  - mammary carcinoma, 105
  - structure, 757
- progesterone response element
  - 627
- prolactin
  - evolutionary origin, 1379
- prolactin receptor
  - 601
- prolactin secretion
  - GHRH, 1395
  - gonadotropin secretion, 1399
  - LHRH, 1395
  - neural regulation, 1385
  - oxytocin, 1386
  - pulsatility, 1387
  - TRH, 1017, 1394
  - VIP, 1387, 1393
- prolactin synthesis
  - bromocriptine, 563
- prolactinoma
  - arteriogenesis, 559
  - estrogen, 559
  - etiology, 559
  - immunocytochemistry, 554
  - medical treatment, 579
  - TRH, 556
- proopiomelanocortin
  - gene expression, 1119
  - synthesis, 737
- prostate
  - androgen metabolism, 293
  - aromatase, 294
  - estrogen action, 289
  - inhibin, 301
- prostate carcinoma
  - buserelin, 307
  - cyproterone acetate, 308
  - endocrine therapy, review, 307
  - flutamide, 308
  - pathobiology, review, 287
- prostate hyperplasia
  - pathobiology, review, 287
- protein disulfide isomerase
  - T3 binding protein, 783
- protein kinase
  - FSM, 1039
  - ovary, 1040
- psychiatric disorder
  - CRF, 901
- PTH-like peptide
  - structure, 1359
  - tumor hypercalcemia, 1357
- puabain
  - sodium transport, 365

- puberty
  - bird, 849
  - hypothalamus-pituitary-gonadal axis, rat, 855
  - LH secretion, sheep, 861
  - LHRH secretion, 856
- pulsatile secretion
  - insulin, 125
  - LHRH, 421
- ranatensin
  - bombesin-like peptide, 1233
- renin
  - adrenal gland, 837
  - aldosterone production, 837
  - follicle fluid, 1201
  - Leydig cell, 1208
- renin-angiotensin system
  - hypertension, 1089
  - immunocytochemistry, 1197
  - in situ hybridization, 1197
  - ovary, 1201
  - testis, 1207
- restriction fragment length polymorphism
  - diabetes mellitus, 1460
- restriction length polymorphism
  - 21-hydroxylase deficiency, 489
- retinol binding protein
  - estrogen, 635
- retinopathy
  - pancreas transplantation, 674
- rhodopsin receptor
  - 37
- riboflavin carrier protein
  - estrogen, 343
- secretogranin
  - 326
- semen
  - aging, 268
- serotonin
  - LHRH secretion, 437
- Sertoli cell
  - androgen binding protein, 1166
  - calcium phospholipid pathway, 1045
  - cAMP, 1045
  - cell-cell interaction, 1145
  - growth factor, 1154
  - IGF-1, 1164
  - Leydig cell interaction, 1151
  - second messenger, 1045
  - testibumin, 459
  - testin, 1157
  - transferrin, 1164
- sex hormone binding globulin
  - structure, 1308
- sexual arousal
  - VIP, 1286
- sexual differentiation
  - LHRH deficiency, 525
  - short stature
    - GH treatment, 825
    - treatment, 1449
  - signal peptide
    - fibroblast growth factor, 517
  - sodium transport
    - aldosterone, 362
    - amiloride, 364
    - ouabain, 365
  - somatomedin C
    - bone formation, 916
  - somatostatin
    - acromegaly, 581
    - acromegaly, treatment, 10
    - fetal pituitary, 697
    - GH-secretion, 6, 811
    - insulin secretion, 128
  - somatostatin analog
    - acromegaly, 1369
    - carcinoid, 1371
    - endocrine pancreas tumor, 1371
  - somatostatin gene
    - 90
  - somatostatin secretion
    - somatotropic adenoma, 556
  - somatotropic adenoma
    - immunocytochemistry, 554
    - somatostatin secretion, 556
  - steroid binding protein
    - exercise, 1323
    - general diseases, 1322
    - malnutrition, 1323
    - molecular characteristic, 1305
    - ontogeny, 1319
    - review, 1297
  - steroid hormone binding protein
    - tissue difference, 1313
  - steroid receptor
    - breast cancer, 1415
  - steroid response element
    - 619
  - steroidogenesis
    - cytochrome P450 enzyme, 477
    - deglycosylated LH, 1027
    - ovary-renin-angiotensin, 1204
  - steroidogenic enzyme
    - ovarian cells, 208
  - stress
    - central nervous system, 355
    - corticosteroid receptor, 355
  - stress response
    - CRF, 904
  - substance K
    - 25
  - substance P
    - 25
    - urogenital tract, 1283
  - sugar chain structure
    - glycoprotein hormone, 743



- superoxide dismutase
  - endemic goiter, 1338
  - iodine deficiency, 1333
- T-cell subset
  - thyroid gland, 1328, 1553
- T3
  - binding protein, cell membrane, 779
  - GH-cell, 785
  - growth factor, 788
  - malic enzyme mRNA, 791
  - pituitary cell culture, 785
- tachykinin
  - neuropeptide, gene organization, 25
- taxoxifen
  - 106
- testibumin
  - Sertoli cell, 459
- testis
  - aging, size, 269
  - epidermal growth factor, 452
  - opiate antagonist, 466
  - POMC-derived peptides, 457
  - renin-angiotensin-system, 1207
  - Sertoli cell, 1157
- testolactone
  - precocious puberty, 155
- testosterone
  - aging, blood level, 271
  - prostate growth, 288
- testosterone clearance rate
  - free hormone level, 1299
- testotoxicosis
  - familial precocious puberty, 158
- thymic hormone
  - glucocorticoid, 352
- thyrocyte
  - DR antigen expression
- thyroglobulin
  - iodine deficiency, 1333
- thyroid autoimmunity
  - 1409
- thyroid cell
  - cytokine, 1329
- thyroid cell culture
  - growth factors, 1063
- thyroid function
  - pregnancy, 1453
- thyroid growth
  - goiter, 1053
  - growth factor, 1063
  - immunoglobins, 1077
  - iodine, 1071
  - review, 1055
- thyroid growth stimulating globulin
  - 1077
- thyroid hormone resistance
  - 797
- thyroid microsomal-peroxidase
  - antigen, 1551
- thyroid stimulator
  - autoimmunity, 1327
- thyroid T-cell
  - interferon, 1554
  - tumor necrosis factor, 1554
- thyroid-stimulating antibody
  - 1410
- thyrototoxic periodic paralysis
  - pathogenesis, 1342
- thyrotropin releasing hormone
  - see TRH
- transcortin
  - corticoid derivative binding, 1314
- transducin
  - 37
- transferrin
  - Sertoli cell, 1164
- transforming growth factor
  - gonads, 453
- transforming growth factor beta
  - bone resorption, 927
  - osteoblast, 928
  - review, 509
- TRH
  - GH secretion, acromegaly, 9
  - inositol lipid metabolism, 1017
  - prolactin secretion, 1017, 1394
  - prolactinoma, 556
- triiodothyronine
  - see T3
- TSH
  - inappropriate secretion, 798
- TSH blocking antibody
  - 1552
- TSH deficiency
  - congenital hypothyroidism, 545
- TSH receptor
  - 609
- TSH receptor antibody
  - 609
- TSH-binding inhibitor
  - Graves' disease, 1409
- TSH-gene
  - hypothyroidism, 545
- TSH-receptor antibody
  - Graves' disease, 1410
  - hypothyroidism, 1411
- tumor growth factor alpha
  - adenocarcinoma, 1363
- tumor necrosis factor
  - beta cell destruction, 666
- tumour growth factor
  - mammary carcinoma, 97
- Turner syndrome
  - GH treatment, 826
- tyrosine
  - sulfation, 325
- uncoupling protein
  - brown fat, 717

- norepinephrine, 719
- obesity, 719
- urogenital tract
  - vasoactive peptide, 1283
- vascular smooth muscle
  - neuropeptide Y, 1291
- vasoactive intestinal polypeptide
  - gut receptor, 1227
  - see also VIP
- vasoactive peptide
  - urogenital tract, 1283
- vasopressin
  - ACTH-secretion, 5
  - adrenal cortex, 831
  - adrenal insufficiency, 1273
  - aldosterone production, 831
  - ANP innervation, 175
  - Brattleboro rat, 537
  - cardiac output, 1270
  - cardiovascular effects, 1269
  - central nervous system, 1171
  - fetus, 685
  - gonad, 469
  - Leydig cell, 1180
- vasopressin gene
  - 537
- vasopressin precursor
  - Brattleboro rat, 1177
- vasopressin receptor
  - review, 1183
- vasopressin secretion
  - hemorrhage, 1272
  - osmoreceptor, 1189
- VIP
  - adrenal cortex, 841
  - erection, 1286
  - insulin secretion, 120
  - prolactin secretion, 1393
  - pulsatile prolactin secretion, 1387
  - sexual arousal, 1286
- VIP receptor
  - functional property, 1227
- vitamin D metabolite
  - osteoporosis, 1249
- vitamin D receptor
  - regulation, 766
  - review, 763
  - structure, 765
- vitamin D3
  - osteoporosis, 1242
- vitamin E
  - adrenal gland, 279
- vitellogenin
  - estrogen, 633
  - gene transcription, 633